ResearcherInsermNo recent work listed
Assia L. Angelova
Matched on ORCID iD 0000-0003-2349-0404; OpenAlex author ID A5020443258. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2011: 2 papers · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 6
- Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
- A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
- The Promise of Gene Therapy for Pancreatic Cancer. First author DOI 10.1089/hum.2015.141↗
- Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. Co-author DOI 10.1128/jvi.03688-13↗
- Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. First author DOI 10.1155/2011/741868↗
- Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Co-author DOI 10.4161/cbt.12.10.17678↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dirk Jäger · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Christine E. Engeland · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Guy Ungerechts · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Niels Halama · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Christoph Springfeld · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Jacek Hajda · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Nicolas Hohmann · 1 shared paper, 2021 · strength 0.10
- Matthias M. Gaida · 1 shared paper, 2021 · strength 0.10
- Svitlana P. Grekova · 3 shared papers, 2011–2014 · strength 0.10
- Paper Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. DOI 10.1155/2011/741868↗
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Zahari Raykov · 3 shared papers, 2011–2014 · strength 0.10
- Paper Pancreatic cancer cell lines can induce prostaglandin e2 production from human blood mononuclear cells. DOI 10.1155/2011/741868↗
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Georges Vassaux · 1 shared paper, 2016 · strength 0.07
- Pierre Cordelier · 1 shared paper, 2016 · strength 0.07
- Nathalia A. Giese · 2 shared papers, 2011–2014 · strength 0.06
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Marc Aprahamian · 2 shared papers, 2011–2014 · strength 0.06
- Paper Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. DOI 10.1128/jvi.03688-13↗
- Paper Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinoma… DOI 10.4161/cbt.12.10.17678↗
- Albrecht Stenzinger · 1 shared paper, 2017 · strength 0.05
- Jens Werner · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.